Table 3. Site-specific risk of second cancer following CLL by age at first diagnosis and follow-up time.
|
Age at CLL diagnosis
a
|
Year(s) after CLL diagnosis
|
|||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
40–54
|
55–64
|
>64
|
<1
|
1-9
|
>9
|
|||||||
| Second cancer site (ICD-10) | O | SIR | O | SIR | O | SIR | O | SIR | O | SIR | O | SIR |
| Lip (C00) | 11 | 56.5 | 9 | 8.83 | 25 | 4.95 | 2 | 3.83 | 31 | 6.61 | 12 | 16.5 |
| Colorectal (C18–C20; C218) | 12 | 2.32 | 60 | 2.58 | 175 | 1.82 | 27 | 2.72 | 182 | 2.01 | 38 | 1.98 |
| Lung (C33–C34) | 19 | 2.70 | 87 | 2.78 | 169 | 1.92 | 25 | 2.51 | 191 | 2.08 | 59 | 2.43 |
| Melanoma (C44; M872–M879) | 32 | 22.0 | 70 | 11.0 | 169 | 6.20 | 17 | 6.11 | 206 | 8.04 | 49 | 7.51 |
| Female Breast (C50) | 9 | 4.41 | 21 | 3.04 | 56 | 1.58 | 8 | 2.22 | 64 | 1.96 | 14 | 2.38 |
| Uterine corpus (C54) | 0 | — | 7 | 5.39 | 2 | 3.25 | 1 | 1.67 | 21 | 3.86 | 4 | 9.77 |
| Prostate (C61) | 13 | 4.54 | 70 | 3.02 | 184 | 1.64 | 38 | 3.47 | 171 | 1.67 | 59 | 2.38 |
| Kidney (C64–C66, C68) | 7 | 7.11 | 15 | 3.48 | 31 | 2.06 | 8 | 5.01 | 36 | 2.43 | 9 | 4.29 |
| Bladder (C67) | 1 | 1.38 | 15 | 3.17 | 55 | 2.30 | 6 | 2.49 | 47 | 2.19 | 18 | 3.61 |
| All malignant neoplasms (C00–C80) | 140 | 3.84 | 467 | 2.89 | 1183 | 1.89 | 163 | 2.50 | 1270 | 2.11 | 360 | 2.25 |
Abbreviations: CLL=chronic lymphocytic leukaemia; ICD=International Classification of Diseases; O=observed number of cases; SIR= standardised incidence ratio.
a
Age group <40 years was excluded from table because of small numbers.
Values in bold=95% confidence interval did not include 1.00; cancer types must have been significant (95% confidence interval did not include 1.00) and have at least 20 cases to be included.